Last month, Pfizer ($PFE) said it was "delighted" with the Phase II results of palbociclib, its in-development breast cancer drug, fanning expectations that the drugmaker might make its case to the FDA before embarking on a late-stage study. Now, with Pfizer expected to get into specifics on the breakthrough-designated therapy at this weekend's American Association for Cancer Research meeting in San Diego, analysts will be all ears as the company sheds light on its would-be blockbuster. More